PrEP Promotion for Human Immunodeficiency Virus Infection

Charles R. Drew University of Medicine and Science, Los Angeles, CA
Entre Herman@s +1 moreN/ARecruitingLed by Homero del Pino, PhD, MSResearch Sponsored by Charles Drew University of Medicine and Science

Study Summary

This trial aims to reduce HIV incidence among Latino gay men by training siblings to promote PrEP use. Control group will talk about vaccines to prevent other diseases.

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You are open to discussing healthcare issues related to men who have sex with men (MSM) with your sibling.


Screening ~ 3 weeks
Treatment ~ Varies
Follow ups ~ 90 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants that get vaccinated
Number of participants that start using PrEP
Secondary outcome measures
Number of participants who increase their willingness to get vaccinated
Number of participants who increase their willingness to use PrEP

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: PrEP PromotionExperimental Treatment1 Intervention
Group II: Vaccine PromotionPlacebo Group1 Intervention

Find a site

Who is running the clinical trial?

Charles Drew University of Medicine and ScienceLead Sponsor
50 Previous Clinical Trials
6,139 Total Patients Enrolled
St. John's Community HealthUNKNOWN
Homero del Pino, PhD, MSPrincipal Investigator
Charles Drew University of Medicine and Science

Media Library

Entre Herman@s Clinical Trial Eligibility Overview. Trial Name: NCT05805306 — N/A
Human Immunodeficiency Virus Infection Research Study Groups: PrEP Promotion, Vaccine Promotion
Human Immunodeficiency Virus Infection Clinical Trial 2023: Entre Herman@s Highlights & Side Effects. Trial Name: NCT05805306 — N/A
Entre Herman@s 2023 Treatment Timeline for Medical Study. Trial Name: NCT05805306 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the eligibility criteria for this clinical trial encompass individuals aged thirty and above?

"As specified by the inclusion criteria, only individuals aged between 18 and 39 are eligible for this trial. Conversely, there are 112 trials specifically tailored to minors and 338 studies reserved for geriatric patients."

Answered by AI

How many individuals are contributing to this research effort?

"Affirmative. Per the information sourced on, this medical trial is actively looking for participants and was first posted to the website on April 15th 2023. Last updated on 4/6/2023, it seeks 248 patients from a single site of recruitment."

Answered by AI

Is the recruitment period of this trial still ongoing?

"Affirmative. reveals that this clinical trial is actively recruiting participants, which began on April 15th 2023 and was last updated 6 days later. The study has a requirement of 248 patients from 1 medical centre."

Answered by AI

Is it possible to join the research trial?

"In order to have the opportunity to participate, applicants must be infected with HIV and between 18-39 years of age. There is an overall target recruitment quota of 248 patients for this trial."

Answered by AI
~110 spots leftby Feb 2024